We are live on ! Find out more
CRVS icon

Corvus Pharmaceuticals
CRVS

47 hedge funds and large institutions have $31.9M invested in Corvus Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more call options, than puts

Call options by funds: $79K | Put options by funds: $73K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2% less funds holding

Funds holding: 48 → 47 (-1)

3.15% less ownership

Funds ownership: 39.65% → 36.5% (-3.1%)

7% less capital invested

Capital invested by funds: $34.2M → $31.9M (-$2.36M)

13% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 8

29% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 14

Holders
47
Holders Change
-1
Holders Change %
-2.08%
% of All Funds
0.68%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
7
Increased
10
Reduced
14
Closed
8
Calls
$79K
Puts
$73K
Net Calls
+$6K
Net Calls Change
+$77K

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$298K
2
BCM
Bridgeway Capital Management
Texas
+$157K
3
JP Morgan Chase
JP Morgan Chase
New York
+$109K
4
Renaissance Technologies
Renaissance Technologies
New York
+$104K
5
QOP
Quinn Opportunity Partners
Virginia
+$46.6K

Top Sellers

1
BI
BVF Inc
California
-$2.11M
2
Morgan Stanley
Morgan Stanley
New York
-$509K
3
SC
Samlyn Capital
New York
-$309K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$241K
5
Two Sigma Investments
Two Sigma Investments
New York
-$163K
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$27.9K – – –
VF
27
Virtu Financial
New York
$22K +$26.3K +12,570 New
Dimensional Fund Advisors
28
Dimensional Fund Advisors
Texas
$21.2K – – –
TRCT
29
Tower Research Capital (TRC)
New York
$20.5K +$6.28K +3,008 +35%
AIM
30
Avity Investment Management
Connecticut
$20.4K – – –
WTC
31
WhitTier Trust Company
Nevada
$19.8K – – –
FFG
32
Fortem Financial Group
California
$19.6K +$23K +11,000 New
MTWM
33
Masso Torrence Wealth Management
New Jersey
$17.8K – – –
Simplex Trading
34
Simplex Trading
Illinois
$16K -$84.1K -40,285 -81%
RIL
35
Rothschild Investment LLC
Illinois
$12.5K +$14.6K +7,000 New
UBS Group
36
UBS Group
Switzerland
$8.33K -$4.22K -2,021 -30%
Group One Trading
37
Group One Trading
Illinois
$8.2K -$67K -32,060 -87%
NCM
38
Northwest Capital Management
Oregon
$6.05K – – –
Qube Research & Technologies (QRT)
39
Qube Research & Technologies (QRT)
United Kingdom
$4.23K +$4.97K +2,378 New
Osaic Holdings
40
Osaic Holdings
Arizona
$2.14K – – –
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$1.41K – – –
Wells Fargo
42
Wells Fargo
California
$472 +$10 +5 +2%
IGWM
43
ICA Group Wealth Management
Colorado
$294 +$345 +165 New
IA
44
IFP Advisors
Florida
$43 – – –
PA
45
Parallel Advisors
California
$36 – – –
Fidelity Investments
46
Fidelity Investments
Massachusetts
$30 +$36 +17 New
Barclays
47
Barclays
United Kingdom
$2 – – –
MA
48
MYDA Advisors
New York
– -$125K -71,011 Closed
XT
49
XTX Topco
Cayman Islands
– -$41.2K -23,415 Closed
Jane Street
50
Jane Street
New York
– -$40.6K -23,095 Closed
1
2
3

CRVS Hedge Fund Activity: Q1 2024 in Review

47 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q1 2024, worth a combined $31.9M — down 6.9% from $34.2M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of CRVS and 7 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 10 added.

The largest buyer was Vanguard Group, adding an estimated $298K. The largest seller was BVF Inc, cutting an estimated $2.11M.

  • 47 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q1 2024, down from 48 in Q4 2023.
  • Funds reported $31.9M of Corvus Pharmaceuticals stock for Q1 2024, down 6.9% quarter-over-quarter.
  • 7 funds opened new Corvus Pharmaceuticals positions in Q1 2024 and 8 closed out, a net change of -1 holder.
  • The largest Corvus Pharmaceuticals buyer in Q1 2024 was Vanguard Group, an estimated $298K added.
  • The largest Corvus Pharmaceuticals seller in Q1 2024 was BVF Inc, an estimated $2.11M sold.

Based on aggregated 13F filings for Q1 2024.